US-based medication savings company GoodRx (Nasdaq: GDRX) announced on Monday that it has partnered with healthcare company Novo Nordisk to make all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens available to eligible self-paying patients for USD499 per month, effective immediately.

This marks the first time Ozempic is accessible at this price point, expanding affordability for patients lacking adequate insurance coverage.

Demand for GLP-1 medications has surged, with nearly 17 million people seeking information and savings on these treatments via GoodRx over the past year, a 22% increase from the prior year. The platform will leverage its scale to improve access to these FDA-approved therapies, which are prescribed for type 2 diabetes and obesity but often face insurance barriers. GoodRx research indicates 19 million people currently lack coverage for weight-loss GLP-1 medications.

Eligible patients can now use GoodRx to self-pay at over 70,000 retail pharmacies nationwide. GoodRx serves nearly 30 million consumers and over one million healthcare professionals annually, connecting patients, providers, payers and pharmacies to reduce friction, improve access, and cut costs. Since 2011, GoodRx has helped Americans save more than USD85bn on medications.